dihexa renal toxicity study (PNB-0408) | c-Met/HGFR Activator Transcriptomic profiling and differential analysis
Description
doi:10.1001/jama.286.7.821
Retatrutide is a triple agonist acting on GLP-1, GIP, and glucagon receptors, with phase 2 data published in the New England Journal of Medicine (2023) showing substantial weight reduction
The human data is almost nonexistent
[DOI] [PMC free article] [PubMed] [Google Scholar] 330.Costford, S
